Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors
Ben Tran, Richard D Carvajal, Aurelien Marabelle, Sandip Pravin Patel, Patricia M LoRusso, Erik Rasmussen, Gloria Juan, Vijay V Upreti, Courtney Beers, Gataree Ngarmchamnanrith, Patrick Schoffski
Journal for ImmunoTherapy of Cancer | BMC | Published : 2018
Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
This study was funding by Amgen Inc., who sponsored the trial and whose employees were involved in the study design, data analysis, and interpretation of the data.